IRIDEX Balance Sheet Health
Financial Health criteria checks 5/6
IRIDEX has a total shareholder equity of $4.7M and total debt of $3.8M, which brings its debt-to-equity ratio to 79.6%. Its total assets and total liabilities are $28.3M and $23.5M respectively.
Key information
79.56%
Debt to equity ratio
US$3.77m
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.60m |
| Equity | US$4.73m |
| Total liabilities | US$23.54m |
| Total assets | US$28.27m |
Recent financial health updates
Is IRIDEX (NASDAQ:IRIX) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Recent updates
Growing Laser Glaucoma Adoption And Cost Restructuring Will Support A Stronger Long Term Outlook
Catalysts About IRIDEX IRIDEX develops and sells ophthalmic laser systems and related disposable products for glaucoma and retina procedures worldwide. What are the underlying business or industry changes driving this perspective?Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive
IRIDEX Corporation ( NASDAQ:IRIX ) shareholders won't be pleased to see that the share price has had a very rough...Is IRIDEX (NASDAQ:IRIX) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Iridex's Strategic Review Process Should Bear Fruit 'Soon'
Summary Iridex Corporation is undergoing a strategic review process to unlock shareholder value. The company is likely to sell its retina business line and potentially parse it out in more than one transaction "soon." The glaucoma business line is highly promising but likely needs to be in the hands of a bigger company to reach its full potential. The entire business may be worth double the current share prices, in line with what Topcon paid three years ago to acquire a 10% stake. Read the full article on Seeking AlphaLittle Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.7x IRIDEX Corporation ( NASDAQ:IRIX ) is definitely a...Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop
IRIDEX Corporation ( NASDAQ:IRIX ) shareholders that were waiting for something to happen have been dealt a blow with a...Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Financial Position Analysis
Short Term Liabilities: IRIX's short term assets ($24.6M) exceed its short term liabilities ($12.8M).
Long Term Liabilities: IRIX's short term assets ($24.6M) exceed its long term liabilities ($10.7M).
Debt to Equity History and Analysis
Debt Level: IRIX has more cash than its total debt.
Reducing Debt: IRIX's debt to equity ratio has increased from 9.6% to 79.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IRIX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IRIX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 19.3% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 18:16 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/04/04 |
| Annual Earnings | 2026/01/03 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IRIDEX Corporation is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Scott Henry | Roth Capital Partners |
| Joseph Munda | Sidoti & Company, LLC |